Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2018

View Archived Issues

Deleterious mutations in SQSTM1 cause early onset neurodegeneration

Cannabis-schizophrenia association goes both ways, but unequally

How cirrhosis drug fights Alzheimer's disease

HDAC inhibition can help in DNA repair syndrome

Methylation of MORC1 predicts depression risk in humans

RegenxBio announces development of new candidate RGX-181 for CLN2 form of Batten disease

Phase I trial of Adverum's ADVM-022 gene therapy for wAMD to begin in Q4

Initial single-dose data presented from phase I study of NasoShield

Darzalex receives approval in Europe as treatment of newly diagnosed multiple myeloma

FKBP5 strikes again: Gene variant affects risk of developing chronic pain after trauma

MAP17 levels predict sensitivity of lung adenocarcinoma to chemotherapy

Development of a universally effective influenza virus

Capella BioSience describes antibodies targeting LIGHT

Invictus Oncology patents CSF1R inhibitors

Nuclear receptor RORgammaT agonists synthesized at Fudan University

Praxis Precision Medicines discovers sodium channel protein type 8 subunit alpha blockers

Cavion divulges new calcium channel inhibitors

FDA issues complete response letter for dasotraline NDA for ADHD

European Commission approves Cablivi for acquired thrombotic thrombocytopenic purpura

Incyte studies INCAGN-02385 in phase I for advanced malignancies

New phase II trial investigates MT-3724 with GEMOX in NHL

AstraZeneca conducts first-in-human study of AZD-8154 in healthy subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...